OBJECTIVE: Determine if employment-based reinforcement can increase methadone treatment engagement and drug abstinence in out-of-treatment injection drug users. METHOD: This study was conducted from 2008 to 2012 in a therapeutic workplace in Baltimore, MD. After a 4-week induction, participants (N=98) could work and earn pay for 26 weeks and were randomly assigned to Work Reinforcement, Methadone & Work Reinforcement, and Abstinence, Methadone & Work Reinforcement conditions. Work Reinforcement participants had to work to earn pay. Methadone &; Work Reinforcement and Abstinence, Methadone, &; Work Reinforcement participants had to enroll in methadone treatment to work and maximize pay. Abstinence, Methadone, &; Work Reinforcement participants had to provide opiate- and cocaine-negative urine samples to maximize pay. RESULTS: Most participants (92%) enrolled in methadone treatment during induction. Drug abstinence increased as a graded function of the addition of the methadone and abstinence contingencies. Abstinence, Methadone &; Work Reinforcement participants provided significantly more urine samples negative for opiates (75% versus 54%) and cocaine (57% versus 32%) than Work Reinforcement participants. Methadone &; Work Reinforcement participants provided significantly more cocaine-negative samples than Work Reinforcement participants (55% versus 32%). CONCLUSION: The therapeutic workplace can promote drug abstinence in out-of-treatment injection drug users. Clinical trial registration number: NCT01416584.
RCT Entities:
OBJECTIVE: Determine if employment-based reinforcement can increase methadone treatment engagement and drug abstinence in out-of-treatment injection drug users. METHOD: This study was conducted from 2008 to 2012 in a therapeutic workplace in Baltimore, MD. After a 4-week induction, participants (N=98) could work and earn pay for 26 weeks and were randomly assigned to Work Reinforcement, Methadone & Work Reinforcement, and Abstinence, Methadone & Work Reinforcement conditions. Work Reinforcement participants had to work to earn pay. Methadone & Work Reinforcement and Abstinence, Methadone, & Work Reinforcement participants had to enroll in methadone treatment to work and maximize pay. Abstinence, Methadone, & Work Reinforcement participants had to provide opiate- and cocaine-negative urine samples to maximize pay. RESULTS: Most participants (92%) enrolled in methadone treatment during induction. Drug abstinence increased as a graded function of the addition of the methadone and abstinence contingencies. Abstinence, Methadone & Work Reinforcement participants provided significantly more urine samples negative for opiates (75% versus 54%) and cocaine (57% versus 32%) than Work Reinforcement participants. Methadone & Work Reinforcement participants provided significantly more cocaine-negative samples than Work Reinforcement participants (55% versus 32%). CONCLUSION: The therapeutic workplace can promote drug abstinence in out-of-treatment injection drug users. Clinical trial registration number: NCT01416584.
Authors: Steffanie A Strathdee; Erin P Ricketts; Steven Huettner; Lee Cornelius; David Bishai; Jennifer R Havens; Peter Beilenson; Charles Rapp; Jacqueline J Lloyd; Carl A Latkin Journal: Drug Alcohol Depend Date: 2005-12-20 Impact factor: 4.492
Authors: Michael Kidorf; Van L King; Neeraj Gandotra; Ken Kolodner; Robert K Brooner Journal: Drug Alcohol Depend Date: 2011-12-31 Impact factor: 4.492
Authors: Louisa Degenhardt; Bradley Mathers; Mauro Guarinieri; Samiran Panda; Benjamin Phillips; Steffanie A Strathdee; Mark Tyndall; Lucas Wiessing; Alex Wodak; John Howard Journal: Int J Drug Policy Date: 2010-02-01
Authors: Robert P Schwartz; David A Highfield; Jerome H Jaffe; Joseph V Brady; Carol B Butler; Charles O Rouse; Jason M Callaman; Kevin E O'Grady; Robert J Battjes Journal: Arch Gen Psychiatry Date: 2006-01
Authors: Kelly E Dunn; Anthony Defulio; Jeffrey J Everly; Wendy D Donlin; Will M Aklin; Paul A Nuzzo; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman Journal: Exp Clin Psychopharmacol Date: 2012-12-03 Impact factor: 3.157
Authors: August F Holtyn; Mikhail N Koffarnus; Anthony DeFulio; Sigurdur O Sigurdsson; Eric C Strain; Robert P Schwartz; Kenneth Silverman Journal: J Appl Behav Anal Date: 2014-10-08
Authors: Michael G McDonell; Emily Leickly; Sterling McPherson; Jordan Skalisky; Debra Srebnik; Frank Angelo; Roger Vilardaga; Jenny R Nepom; John M Roll; Richard K Ries Journal: Am J Psychiatry Date: 2017-01-31 Impact factor: 18.112
Authors: August F Holtyn; Forrest Toegel; Shrinidhi Subramaniam; Brantley P Jarvis; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: J Epidemiol Community Health Date: 2020-02-21 Impact factor: 3.710